Respiratory InfectionPhase 2NCT01102374
Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents
A Phase 2 study testing High Dose Vitamin D and Standard Dose Vitamin D in people with Respiratory Infection, run by University of Colorado, Denver at 1 site in United States.
Trial summary
This study will test the role of high dose vitamin D supplementation in prevention of acute respiratory infection in older nursing home residents. The investigators hypothesize that residents on high dose vitamin D supplementation will have a lower incidence of acute respiratory infection that those on standard dose… Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Respiratory Infection
- What is being tested?
- High Dose Vitamin D and Standard Dose Vitamin D
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 107 participants
- Where
- 1 siteUnited States
- Study dates
- May 2010to Jul 2016
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 60+ years
- Resides in nursing home
Who cannot join
- Terminal illness (expected survival <6 months)
- Anticipated discharge within 12 months
- Unable to take whole or crushed tablets
- Active cancer, except squamous/basal cell carcinoma
- Severe malnutrition (body mass index <18 kg/m2)
- Current immunosuppressive medications (including corticosteroids)
Show all 14Show fewer
- Renal failure (estimated glomerular filtration rate < 15 mL/min/1.73m2)
- Currently taking >1,000 IU/d vitamin D supplementation
- History (or strong family history) of kidney stones
- History of sarcoidosis or other granulomatous disorders associated with hypercalcemia
- Elevated baseline hypercalcemia (albumin-adjusted serum calcium >10.5 mg/dL)
- Baseline serum 25OHD level ≥ 100 nmol/L
- Inability to provide informed consent and no available healthcare legally authorized representative
- Inability of participant or legally authorized representative to speak/understand English
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Colorado Denver
Aurora, Colorado, 80045
About this study
This study will test the role of high dose vitamin D supplementation in prevention of acute respiratory infection in older nursing home residents. The investigators hypothesize that residents on high dose vitamin D supplementation will have a lower incidence of acute respiratory infection that those on standard dose vitamin D supplementation.
Read the detailed description
This study is a double-blinded, parallel group, randomized controlled phase II trial of oral high vs. standard dose vitamin D3 supplementation administered monthly for 12 months.
- Conditions
- Respiratory Infection
- Being tested
- High Dose Vitamin D, Standard Dose Vitamin D, Placebo, Usual Care
- Keywords
- Vitamin D Deficiency, Respiratory Infection, Nursing Home Residents, Geriatrics, Immunosenescence, Prevention
- Medical subject headings
- Respiratory Tract Infections, Vitamin D Deficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High Dose Vitamin DDrug
Vitamin D3 100,000 IU monthly
Standard Dose Vitamin DDrug
Vitamin D 12,000 IU monthly
PlaceboDrug
Placebo monthly
Usual CareDietary supplement
Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
| Study group | Role | What they receive |
|---|---|---|
| High Dose Vitamin D | Experimental | 100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. Receives: Drug: High Dose Vitamin D; Dietary Supplement: Usual Care |
| Standard Dose Vitamin D | Active comparator | 12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Receives: Drug: Standard Dose Vitamin D; Drug: Placebo; Dietary Supplement: Usual Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Acute Respiratory Infections (ARIs)
ARIs defined as upper or lower respiratory infections
Measured: 12 months
Secondary outcomes (14)
Severity of Acute Respiratory Infections
ARIs resulting in emergency department visits or hospitalizations
Measured: 12 month
Time to First ARI
Measured: 12 months
Change in 25-hydroxyvitamin D (25OHD) Level
Measured: Baseline and 12 months
Change in Parathyroid Hormone Level
Measured: Baseline and 12 months
Falls
Measured: 12 months
Fractures
Measured: 12 months
Number of Upper Respiratory Infections
Measured: 12 months
Number of Lower Respiratory Infections
Measured: 12 months
Number of Influenza-like Illnesses
Measured: 12 months
Incident Kidney Stones
Measured: 12 months
Incident Hypercalcemia
Measured: 12 months
Death
Measured: 12 months
Number of Urinary Tract Infections
Measured: 12 months
Number of Other Infections
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2010 (estimated)
- Study startMay 2010
- Primary completionAug 2014
- Study completionJul 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Respiratory InfectionStudies of the same condition, open and under way.
- More trials run by University of Colorado, DenverThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 107 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Colorado, Denver
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA), The American Geriatrics Society
- Responsible party
- Sponsor
- Investigators
- Adit A Ginde, MD, MPH, Principal investigator, University of Colorado, Denver
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01102374
- Sponsor's protocol ID
- 09-0899
- Other IDs
- IND 106541, K23AG040708
- Status last verified
- Apr 2017
- First submitted
- 11 Apr 2010
- Last updated
- 21 Apr 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ginde AA, Blatchford P, Breese K, Zarrabi L, Linnebur SA, Wallace JI, Schwartz RS. High-Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial. J Am Geriatr Soc. 2017 Mar;65(3):496-503. doi: 10.1111/jgs.14679. Epub 2016 Nov 16.
PubMed 27861708
Study at a glance
From the registry record, last updated by the sponsor on 21 Apr 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents
- ClinicalTrials.gov ID
- NCT01102374
- Acronym / sponsor ID
- 09-0899
- Conditions
- Respiratory Infection
- Keywords
- Vitamin D Deficiency, Respiratory Infection, Nursing Home Residents, Geriatrics, Immunosenescence, Prevention
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 107 participants (actual)
- Lead sponsor
- University of Colorado, DenverUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA), The American Geriatrics Society
- Study start
- May 2010
- Primary completion
- Aug 2014 (actual)
- Study completion
- Jul 2016 (actual)
- First posted
- 13 Apr 2010 (estimated)
- Results
- Posted 21 Apr 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will test the role of high dose vitamin D supplementation in prevention of acute respiratory infection in older nursing home residents. The investigators hypothesize that residents on high dose vitamin D supplementation will have a lower incidence of acute respiratory infection that those on standard dose vitamin D supplementation.
Detailed description
This study is a double-blinded, parallel group, randomized controlled phase II trial of oral high vs. standard dose vitamin D3 supplementation administered monthly for 12 months.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| High Dose Vitamin D | Experimental | Drug: High Dose Vitamin D, Dietary Supplement: Usual Care100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. |
| Standard Dose Vitamin D | Active comparator | Drug: Standard Dose Vitamin D, Drug: Placebo, Dietary Supplement: Usual Care12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Age 60+ years
- Resides in nursing home
Key exclusion criteria (14 listed)
- Terminal illness (expected survival <6 months)
- Anticipated discharge within 12 months
- Unable to take whole or crushed tablets
- Active cancer, except squamous/basal cell carcinoma
- Severe malnutrition (body mass index <18 kg/m2)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High Dose Vitamin DVitamin D3 100,000 IU monthly | Drug | High Dose Vitamin D |
| Standard Dose Vitamin DVitamin D 12,000 IU monthly | Drug | Standard Dose Vitamin D |
| PlaceboPlacebo monthly | Drug | Standard Dose Vitamin D |
| Usual CareUsual care of 0-1000 IU vitamin D daily. This is present in both study arms. | Dietary supplement | High Dose Vitamin D, Standard Dose Vitamin D |
Primary outcome
Number of Acute Respiratory Infections (ARIs)
Time frame: 12 months
ARIs defined as upper or lower respiratory infections
14 secondary outcomes
Severity of Acute Respiratory Infections
Time frame: 12 month
Time to First ARI
Time frame: 12 months
Change in 25-hydroxyvitamin D (25OHD) Level
Time frame: Baseline and 12 months
Change in Parathyroid Hormone Level
Time frame: Baseline and 12 months
Falls
Time frame: 12 months
Fractures
Time frame: 12 months
Number of Upper Respiratory Infections
Time frame: 12 months
Number of Lower Respiratory Infections
Time frame: 12 months
Number of Influenza-like Illnesses
Time frame: 12 months
Incident Kidney Stones
Time frame: 12 months
Incident Hypercalcemia
Time frame: 12 months
Death
Time frame: 12 months
Number of Urinary Tract Infections
Time frame: 12 months
Number of Other Infections
Time frame: 12 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Apr 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 27861708Ginde AA, Blatchford P, Breese K, Zarrabi L, Linnebur SA, Wallace JI, Schwartz RS. High-Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial. J Am Geriatr Soc. 2017 Mar;65(3):496-503. doi: 10.1111/jgs.14679. Epub 2016 Nov 16.
- Individual participant dataSharing planned: No
Related trials for Respiratory Infection
Not yet recruitingPhase 2
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
RecruitingPhase 1
A Clinical Trial of V175 and V175A in Healthy Adults
Lower Respiratory Tract Infection
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
Not yet recruiting
Influence of Patient Positioning During Nasal Lavage
Acute Upper Respiratory Tract Infections, Nasal Obstruction
Active, not recruitingPhase 3
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
Respiratory Syncytial Virus Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Adit A Ginde, MD, MPH principal investigator
University of Colorado, Denver
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing High Dose Vitamin D and Standard Dose Vitamin D in people with Respiratory Infection, run by University of Colorado, Denver at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 21 Apr 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Acute Respiratory Infections (ARIs) (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01102374, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2017; AzTrials last refreshed its copy on 8 Nov 2026.